AIkido Pharma Inc.
| NASDAQ: AIKI | Healthcare / Biotechnology / USA |
| 1.07 | -0.0200 | -1.83% | Vol 1.90M | 1Y Perf 47.78% |
| Jun 14th, 2021 16:00 DELAYED |
| BID | 1.07 | ASK | 1.08 | ||
| Open | 1.10 | Previous Close | 1.09 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 95.80M | Earnings Rating | — | |
| Price Range Ratio 52W % | 29.00 | Earnings Date | 5th Aug 2021 |
Today's Price Range 1.071.11 | 52W Range 0.46562.55 | 5 Year PE Ratio Range -0.80005.00 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -0.93% | ||
| 1 Month | 18.26% | ||
| 3 Months | -21.32% | ||
| 6 Months | 78.69% | ||
| 1 Year | 47.78% | ||
| 3 Years | -76.90% | ||
| 5 Years | -88.56% | ||
| 10 Years | -99.98% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 19.49 | |||
ROE last 12 Months | -12.58 | |||
ROA (5Y Avg) | 3.18 | |||
ROA last 12 Months | -12.46 | |||
ROC (5Y Avg) | 38.91 | |||
ROC last 12 Months | -12.71 | |||
Return on invested Capital Q | -5.95 | |||
Return on invested Capital Y | -61.45 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -7.30 | ||||
| 0.94 | ||||
| - | ||||
| 9.20 | ||||
| -19.20 | ||||
| -0.09 | ||||
| 0.94 | ||||
| 1.17 | ||||
| -5 116 050.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 183.70 | ||||
| 184.10 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -92 677.80 | ||||
| -92 677.80 | ||||
| -17 558.70 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2021 | - | -0.07 | - |
| Q02 2020 | - | -0.07 | - |
| Q01 2020 | - | -0.91 | - |
| Q03 2019 | - | -1.38 | - |
| Q02 2019 | - | -0.30 | - |
| Q01 2019 | - | -0.57 | - |
| Q01 2018 | - | -0.23 | - |
| Q02 2017 | - | -0.38 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 5th Aug 2021 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.90M |
| Shares Outstanding | 89.53M |
| Trades Count | 2.86K |
| Dollar Volume | 28.69M |
| Avg. Volume | 12.25M |
| Avg. Weekly Volume | 2.94M |
| Avg. Monthly Volume | 3.52M |
| Avg. Quarterly Volume | 5.44M |
AIkido Pharma Inc. (NASDAQ: AIKI) stock closed at 1.07 per share at the end of the most recent trading day (a -1.83% change compared to the prior day closing price) with a volume of 1.94M shares and market capitalization of 95.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5 people. AIkido Pharma Inc. CEO is Anthony Hayes.
The one-year performance of AIkido Pharma Inc. stock is 47.78%, while year-to-date (YTD) performance is 22.5%. AIKI stock has a five-year performance of -88.56%. Its 52-week range is between 0.4656 and 2.55, which gives AIKI stock a 52-week price range ratio of 29.00%
AIkido Pharma Inc. currently has a PE ratio of -7.30, a price-to-book (PB) ratio of 0.94, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 9.20, a PEG ratio of 2.32, a ROA of -12.46%, a ROC of -12.71% and a ROE of -12.58%. The company’s profit margin is -%, its EBITDA margin is -92 677.80%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from AIkido Pharma Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AIkido Pharma Inc.’s next earnings report date is 05th Aug 2021.
The consensus rating of Wall Street analysts for AIkido Pharma Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AIkido Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AIkido Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AIkido Pharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 27.91, ATR14 : 0.07, CCI20 : 31.23, Chaikin Money Flow : 0.14, MACD : 0.02, Money Flow Index : 61.64, ROC : 1.90, RSI : 51.51, STOCH (14,3) : 33.33, STOCH RSI : 0.33, UO : 48.29, Williams %R : -66.67), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AIkido Pharma Inc. in the last 12-months were:
AIkido Pharma Inc.
AIkido Pharma Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing a antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
CEO: Anthony Hayes
Telephone: +1 703 992-9325
Address: One Rockefeller Plaza, New York 10020, NY, US
Number of employees: 5
